Royalty Report: Drug Discovery, Drugs, Cancer – Collection: 369308


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drug Discovery
  • Drugs
  • Cancer
  • Medical
  • Device
  • Diagnostic
  • ribonucleic acid

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 369308

License Grant
University grants an exclusive license to make, have made, use, market, offer for sale, sell, have sold, import and distribute Licensed Product and practice Licensed Method in the Territory, with the right to issue sublicenses.
License Property
University has an invention, entitled Thioredoxin as a Target for Cancer Chemotherapeutic and Cancer Preventive Drugs.

The Patent Application is entitled Uses of Thioredoxin.

Field of Use
The Licensee claims that this is the first trial of a thioredoxin inhibitor, a class of drug with potential activity against cancers, to be conducted. Thioredoxin is involved in cellular factors that govern cell growth, and abnormally high levels have been found in a number of human primary cancers.

The field of use for the invention is as an anticancer drug, as a screening tool to identify new cancer drugs, and/or as a mitogenic tissue culture reagent.

IPSCIO Record ID: 344542

License Grant
The University grants an exclusive license, under the Licensed Patents, with the right to sublicense through multiple tiers, to make, have made, use, have used, offer for sale, have offered for sale, sell, have sold, import, have imported, export or have exported Licensed Products, and to practice any Licensed Method, within the Field in the Licensed Territory.
License Property
The University has produced inventions pertaining to drug delivery using targeted nanoparticles OCR 1670 and 3070.

The Patents are for Methods of Treatment with Drug Loaded Polymeric Materials.

Field of Use
The Field shall mean the use of Licensed Products containing a polymer and a therapeutic agent for the treatment of cancer. The Field shall specifically exclude the use of Licensed Products for the treatment of brain cancer; for therapeutic or prophylactic cancer vaccines, including where such vaccines incorporate an adjuvant but not an antigen; and for therapeutic or prophylactic vaccines for infectious diseases or allergies.

IPSCIO Record ID: 383615

License Grant
The University grants the right and worldwide, non-exclusive license, with the right to grant sublicenses, in the Field to make, have made, use, sell, offer for sale, and import the Licensed Technology and to practice under the Patent Rights to the end of the term.
License Property
University is the joint owner by assignment with Carnegie Mellon University of certain Patent Rights,

The Patent Rights are titled A Method and Apparatus for Holding Cells.

Field of Use
The Field shall mean human and veterinary cellular imaging in the Cancer Diagnostics Field and the Drug Development Field.

The Cancer Diagnostics Field shall mean diagnostic assays to detem1ine therapeutic efficacy of then-available chemotherapeutics or biologics on cancer or screening assays for the detection of cancer.

The Drug Development Field shall mean research conducted to measure the effect of preclinical, clinical or commercial stage cancer agents on primary or early passage cell strains.

IPSCIO Record ID: 263910

License Grant
The University grants the Israeli Licensor a co-exclusive, world-wide license to make, have made, use, have used, import, sell, have sold, and offer for sale Licensed Products in the Field of Use during the Term.
License Property
The technology relates to microRNA sequences.  The patents are for Anti Micro-RNA Oligonucleotide Molecules;  Pancreatic Islet MicroRNAs and Methods for Inhibiting Same;   DNA Virus MicroRNAs and Methods for Inhibiting Same; and,  Human MicroRNAs and Methods for Inhibiting Same.
Field of Use
The term Field of Use means human and animal therapeutics.

MicroRNAs have been shown to hold tremendous potential as a new class of prospective drug targets with significant therapeutic opportunity.

MicroRNAs (miRNAs) are a recently discovered, naturally occurring form of RNAi. These small RNAs act as protein regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. Since many diseases are caused by the abnormal activity of proteins, the ability to selectively regulate protein activity through microRNAs could provide the means to treat a wide range of human diseases. In addition, microRNA expression levels have been shown to be correlated with various disease states and to hold great potential as diagnostics and prognostic markers

Licensee's lead therapeutic development program for liver cancer (hepatocellular carcinoma or HCC) has so far identified four microRNAs that when inhibited in vitro lead to a decrease in liver cancer cell proliferation.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.